Viela Bio’s (NYSE:VIE) quiet period is set to expire on Tuesday, November 12th. Viela Bio had issued 7,900,000 shares in its public offering on October 3rd. The total size of the offering was $150,100,000 based on an initial share price of $19.00. During Viela Bio’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Several equities research analysts recently commented on VIE shares. Cowen started coverage on shares of Viela Bio in a research report on Monday, October 28th. They issued an “outperform” rating on the stock. Guggenheim started coverage on shares of Viela Bio in a research report on Monday, October 28th. They issued a “buy” rating and a $44.00 price objective on the stock. Morgan Stanley started coverage on shares of Viela Bio in a research report on Monday, October 28th. They issued an “overweight” rating and a $25.00 price objective on the stock. Finally, Goldman Sachs Group started coverage on shares of Viela Bio in a research report on Monday, October 28th. They issued a “buy” rating and a $32.00 price objective on the stock.

VIE opened at $33.00 on Friday. Viela Bio has a 12 month low of $18.20 and a 12 month high of $33.43.

In related news, major shareholder Plc Astrazeneca acquired 425,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were acquired at an average cost of $19.15 per share, with a total value of $8,138,750.00. Also, Director Xiaomeng Tong acquired 36,091 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was bought at an average cost of $18.75 per share, for a total transaction of $676,706.25. Insiders purchased a total of 471,091 shares of company stock worth $8,821,256 over the last ninety days.

About Viela Bio

Viela Bio, Inc, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases.

See Also: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Viela Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viela Bio and related companies with MarketBeat.com's FREE daily email newsletter.